ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

MNKD MannKind Corporation

4.1115
-0.1485 (-3.49%)
After Hours
Last Updated: 17:49:10
Delayed by 15 minutes

Period:

Draw Mode:

Volume 2,259,980
Bid Price 4.11
Ask Price 4.24
News (1)
Day High 4.31

Low
3.17

52 Week Range

High
5.75

Day Low 4.11
Share Name Share Symbol Market Stock Type
MannKind Corporation MNKD NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.1485 -3.49% 4.1115 17:49:10
Open Price Low Price High Price Close Price Previous Close
4.24 4.11 4.31 4.11 4.26
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
7,848 2,259,980 US$ 4.18 US$ 9,447,736 - 3.17 - 5.75
Last Trade Type Quantity Price Currency
17:49:10 formt 200 US$ 4.1115 USD

MannKind Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.11B 270.42M - 198.96M -11.94M -0.04 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

MannKind News

Date Time Source News Article
4/30/202405:05GlobeNewswire Inc.MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201)..
4/29/202405:05GlobeNewswire Inc.MannKind Announces IND Clearance From U.S. FDA to Start..
4/03/202405:00GlobeNewswire Inc.MannKind Repays Certain Debt Obligations
3/26/202415:05GlobeNewswire Inc.MannKind Announces CFO Transition
3/11/202405:05GlobeNewswire Inc.INHALE-3 Study’s Initial Meal Challenge Results Comparing..
3/05/202405:05GlobeNewswire Inc.MannKind Announces New Clinical Data From Inhale-3 Study to..
3/04/202412:01GlobeNewswire Inc.MannKind Corporation Announces Participation at Upcoming..
2/27/202415:05Edgar (US Regulatory)Form 8-K - Current report
2/27/202415:00GlobeNewswire Inc.MannKind Corporation Reports 2023 Fourth Quarter and Full..
2/20/202405:00GlobeNewswire Inc.MannKind Corporation to Hold 2023 Fourth Quarter and Full..
2/15/202405:05GlobeNewswire Inc.MannKind Announces Enrollment Goal Completion of INHALE-1..
2/05/202405:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No MNKD Message Board. Create One! See More Posts on MNKD Message Board See More Message Board Posts

Historical MNKD Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week4.114.404.064.211,800,7850.00150.04%
1 Month4.304.623.974.262,100,658-0.1885-4.38%
3 Months3.245.403.2194.372,988,2450.871526.90%
6 Months3.925.403.173.982,912,2520.19154.89%
1 Year3.855.753.174.202,841,0250.26156.79%
3 Years4.765.752.494.143,418,606-0.6485-13.62%
5 Years1.556.250.803.503,306,0092.56165.26%

MannKind Description

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Your Recent History

Delayed Upgrade Clock